Skip to main content
. 2016 Sep 15;7(45):73697–73710. doi: 10.18632/oncotarget.12048

Figure 7. Carfilzomib enhances DOX-induced apoptosis through activation of SAPK/JNK pathway and inactivation of NF-κB in breast cancer cells.

Figure 7

a. MCF7 cells were left untreated or treated with DOX (0.1μM) plus carfilzomib (0.01μM), or in combination with specific pathway inhibitors (SP600125:JNK inhibitor (1μM); SB203580: p38 inhibitor (1μM); PS1145: IKK inhibitor(1μM)) for 48 h, then cell viability was measured by MTT assays. The data were represented as mean ± SD. *P<0.05 was indicated. b and c. MCF7 cells were incubated with DOX plus carfilzomib, or in combination with SP600125 or PS1145 for the time courses as indicated. Cells were lysed, subjected to SDS-PAGE, and immunoblotted with indicated antibodies. α-Tubulin was used as the loading control.